Positive Feedback of AJ302 from US-FDA reviewers

AnnJi received positive feedback from US-FDA to submit an IND to initiate phase 1 clinical trial of AJ302 for the treatment of chemotherapy induced neuropathy.

AJ302 is a first-in-class HDAC6 selective inhibitor that has been shown to be safe and effective in ameliorating chemotherapy-induced peripheral neuropathy in animals toxicity studies and disease models. AnnJi plans to initiate a phase I clinical safety study in early 2021.